Aphaia Pharma

R&D

At LSX 2025, editor-in-chief Jonah Comstock connected with Dr Steffen Sebastian-Bolz, chief science officer at Aphaia Pharma.

News

Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.